Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlphaBet: Radium-223 and 177Lu-PSMA-I&T in mCRPC
NCT05383079Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Sep 2022
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 PSMA I&T, radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peter MacCallum Cancer Centre. Started Sep 2022; status: active, not recruiting.
02
Drugs
lutetium Lu 177 PSMA I&Tradium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05383079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383079.